Therefore, we prolonged the HFD studies to confirm the improved inflammatory and metabolic phenotype in our T cell IL-6Rα-deficient animals at a later stage of obesity development to potentially validate the feasibility of pharmacological interventions by inhibiting T cell IL-6 signalling in the treatment of obesity-associated insulin resistance. The gene discussed is IL6; the disease is obesity due to melanocortin 4 receptor deficiency.